Mechanisms of EGFR-TKI induced cell death and resistance in EGFR mutant non-small cell lung cancer

被引:0
|
作者
Ko, J. [1 ]
Kim, Y. [1 ]
Park, M. [1 ]
Cui, Z. [1 ]
Ahn, M. [1 ]
Park, K. [1 ]
机构
[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
来源
EJC SUPPLEMENTS | 2008年 / 6卷 / 09期
关键词
D O I
10.1016/S1359-6349(08)71288-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:29 / 30
页数:2
相关论文
共 50 条
  • [41] Immune microenvironment change after acquiring resistance to EGFR TKI therapy in EGFR mutant non-small cell lung cancer
    Kim, Tae-Jung
    Kang, Jin-Hyoung
    Hong, Sook-hee
    [J]. MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [42] Mechanisms and management of 3rd-generation EGFR-TKI resistance in advanced non-small cell lung cancer (Review)
    He, Jingyi
    Huang, Zhengrong
    Han, Linzhi
    Gong, Yan
    Xie, Conghua
    [J]. INTERNATIONAL JOURNAL OF ONCOLOGY, 2021, 59 (05)
  • [43] PD-L1 confers primary resistance to EGFR-TKI in EGFR mutant non-small cell lung cancer via inducing EMT phenotype
    Zhang, Y.
    Liu, T.
    Zeng, Y.
    Zhu, J.
    Du, W.
    Liu, Z.
    Huang, J-A.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [44] Immunotherapy-based therapy as a promising treatment for EGFR-mutant advanced non-small cell lung cancer patients after EGFR-TKI resistance
    Ding, Jianghua
    Ding, Xinjing
    Leng, Zhaohui
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (02) : 187 - 198
  • [45] Bevacizumab to combat EGFR-TKI resistance in a patient with advanced non-small cell lung cancer harboring an EGFR mutation: A case report
    Wang, Zhiyi
    Zhou, Pu
    Li, Guanghui
    [J]. ONCOLOGY LETTERS, 2016, 12 (01) : 356 - 360
  • [46] Role of PARP1-mediated autophagy in EGFR-TKI resistance in non-small cell lung cancer
    Zhimin Zhang
    Xiaojuan Lian
    Wei Xie
    Jin Quan
    Maojun Liao
    Yan Wu
    Zhen-Zhou Yang
    Ge Wang
    [J]. Scientific Reports, 10
  • [47] MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer
    Li, Bing
    Ren, Shengxiang
    Li, Xuefei
    Wang, Yongsheng
    Garfield, David
    Zhou, Songwen
    Chen, Xiaoxia
    Su, Chunxia
    Chen, Mo
    Kuang, Peng
    Gao, Guanghui
    He, Yayi
    Fan, Lihong
    Fei, Ke
    Zhou, Caicun
    Schmit-Bindert, Gerald
    [J]. LUNG CANCER, 2014, 83 (02) : 146 - 153
  • [48] Third generation EGFR TKI landscape for metastatic EGFR mutant non-small cell lung cancer (NSCLC)
    Tan, Aaron C.
    Teh, Yi Lin
    Lai, Gillianne G. Y.
    Tan, Daniel S. W.
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2019, 19 (06) : 431 - 435
  • [49] Apatinib to combat EGFR-TKI resistance in an advanced non-small cell lung cancer patient with unknown EGFR status: a case report
    Peng, Yanmei
    Cui, Huijuan
    Liu, Zhe
    Liu, Daiwei
    Liu, Fan
    Song, Yazhong
    Duan, Hua
    Qiu, Yuqin
    Li, Qiang
    [J]. ONCOTARGETS AND THERAPY, 2017, 10 : 2289 - 2295
  • [50] Molecular Mechanism of EGFR-TKI Resistance in EGFR-Mutated Non-Small Cell Lung Cancer: Application to Biological Diagnostic and Monitoring
    Reita, Damien
    Pabst, Lucile
    Pencreach, Erwan
    Guerin, Eric
    Dano, Laurent
    Rimelen, Valerie
    Voegeli, Anne-Claire
    Vallat, Laurent
    Mascaux, Celine
    Beau-Faller, Michele
    [J]. CANCERS, 2021, 13 (19)